Abstract:stream transcriptional mediator for prostaglandins and fatty acids. It provides a direct link between fatty acid metabolism and control of gene transcription. PPAR-γ is predominantly expressed in adipose tissue, the adrenal glands, and the spleen, and has a dominant regulatory role in the differentiation of cells of adipose lineage.1,2 The development of colorectal cancer is profoundly influenced by prostaglandins and fatty acids, and decreased prostaglandin synthesis prevents or attenuates colon cancer development. Nonsteroidal antiinflammatory drugs (NSAIDs) have been reported to lower the relative risk of colorectal cancer in humans,3 and decrease tumor yield in rodents treated with carcinogens3 or implanted with tumors.4 A well-known target of NSAIDs is prostaglandin endoperoxide synthase (cyclooxygenase, COX) and two isoforms of this enzyme have been identified, namely, COX-1 and COX-2. COX enzymes catalyze the production of eicosanoids, some of which have recently been shown to activate the transcription mediated by PPAR-γ. NSAIDs are also known to directly bind to the PPAR-γ receptor which has been shown to be highly expressed in the normal colonic mucosa,5,6 in colon cancer cell lines,5–8 and in both welland poorly-differentiated adenocarcinomas.5,6 Troglitazone (TZD) has recently been developed as a selective ligand and agonist of PPAR-γ which has been shown to inhibit colon cancer cell growth by the induction of G1 cell-cycle arrest7,8 and cell differentiation,6,7 and the inhibition of anchorageindependent cell growth.8 These facts suggest that TZD could play a role in colorectal cancer tumorigenesis and progression. In the present study, we investigated the effect of TZD on the adhesion of colon cancer cells to extracellular matrix proteins, and on the synthesis of matrix metalloproteinases (MMPs), which are essential events in the development of cancer metastasis. Abstract Purpose. In the present study, we investigated the effect of troglitazone, a selective ligand and agonist of PPAR-γ, on the metastatic potential of human colon cancer cells. Methods. Highand low-PPAR-γ expression clones of the colon cancer cell line, HT29, namely clones 21 and 3 respectively, were used. We investigated the effect of troglitazone on the proliferation, on the adhesion to extracellular matrix proteins and on the synthesis of matrix metalloproteinases (MMPs) of colon cancer cells. Results. Troglitazone inhibited the proliferation of both subclones, in a dose-dependent manner, and the inhibitory effect correlated with the level of PPAR-γ expression. Troglitazone strongly inhibited the production of MMP-7, an enzyme associated with invasiveness of cancer cells, by both subclones. In addition, troglitazone caused a strong decrease in the adhesion of clone 21 to extracellular matrix (ECM) proteins, laminin and type IV collagen. This effect was independent of 1-integrins expression Conclusion. In addition to inhibition of cancer cell growth, troglitazone had an inhibitory effect on two important events associated with the metastatic potential of cancer cells, production of MMPs and adhesion to ECM proteins. Consequently, troglitazone is a promising agent for the treatment and prevention of colon cancer metastasis.

Decreased Synthesis of Matrix Metalloproteinase-7 and Adhesion to the Extracellular Matrix Proteins of Human Colon Cancer Cells Treated with Troglitazone

Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

The mechanism by which tamoxifen attenuates high glucose-induced epithelial-to-mesenchymal transition of rat peritoneal mesothelial cells

[Effects of Peroxisome Proliferator-Activated Receptor-Gamma Ligand Troglitazone on Colon Cancer Cell Growth].

Poster Session AP2: Cell Death and Survival

Troglitazone Sensitizes Effect of Epirubicin on Breast Cancer Cells

Lobeglitazone, A Peroxisome Proliferator-Activated Receptor-Gamma Agonist, Inhibits Papillary Thyroid Cancer Cell Migration and Invasion by Suppressing p38 MAPK Signaling Pathway

Effects of the PPARgamma agonist troglitazone on endothelial cells in vivo and in vitro: differences between human and mouse

Troglitazone Inhibits Cell Proliferation by Attenuation of Epidermal Growth Factor Receptor Signaling Independent of Peroxisome Proliferator-Activated Receptor Γ

Data from <i>Gas1</i> Inhibits Metastatic and Metabolic Phenotypes in Colorectal Carcinoma

Down-regulation of X-linked Inhibitor of Apoptosis Synergistically Enhanced Peroxisome Proliferator-Activated Receptor Γ Ligand-Induced Growth Inhibition in Colon Cancer

The troglitazone derivative EP13 disrupts energy metabolism through respiratory chain complex I inhibition in breast cancer cells and potentiates the antiproliferative effect of glycolysis inhibitntriors

Troglitazone action is independent of adipose tissue.

Gene expression profile in colon cancer cells with respect to XIAP expression status

The Ppar Gamma Agonist Troglitazone Induces Autophagy, Apoptosis And Necroptosis In Bladder Cancer Cells

[Peroxisome Proliferator-Actived Receptor-Gamma Ligand Troglitazone Induces Apoptosis in Renal Cell Carcinoma].

Loss of Xiap Sensitizes Colon Cancer Cells to Ppar Gamma Independent Antitumor Effects of Troglitazone and 15-Pgj2

Transglutaminase 2 promotes epithelial-to-mesenchymal transition by regulating the expression of matrix metalloproteinase 7 in colorectal cancer cells via the MEK/ERK signaling pathway

Terminal differentiation into adipocyte and growth inhibition by PPARγ activation in human A549 lung adenocarcinoma cells

Activation of Glucagon-Like Peptide-1 Receptor Inhibits Tumourigenicity and Metastasis of Human Pancreatic Cancer Cells Via PI3K/Akt Pathway.

Peroxisome Proliferator-Activated Receptor Γ Ligands Induce Cell Cycle Arrest and Apoptosis in Human Renal Carcinoma Cell Lines